
|Articles|October 19, 2011
- ONCOLOGY Nurse Edition Vol 25 No 10
- Volume 25
- Issue 10
Suggested Reading for a Geriatric Oncology Nursing Journal Club
Black B, Herr K, Fine P, et al: The relationship between pain, nonpain symptoms, and quality of life measures in older adults with cancer receiving hospice care. Pain Med 12(6):880–889, 2011.
Advertisement
Articles in this issue
almost 15 years ago
News of Notealmost 15 years ago
Integrative Medicine Conference Calendaralmost 15 years ago
The Complexity of Hereditary Cancer Syndromesalmost 15 years ago
Coenzyme Q10almost 15 years ago
Elder Spousal Grief in the Context of Cancer Caregivingalmost 15 years ago
Our 9/11 Cancer Nursing Connectionalmost 15 years ago
October Is National Breast Cancer Awareness Monthalmost 15 years ago
Counseling Women at High Risk of Ovarian or Endometrial CancerAdvertisement
Related to this article

In the phase 1b CAMMA 1 trial, cevostamab plus pomalidomide and dexamethasone produced overall response rates of 86.2% to 88.0%.

Data from the phase 3 LITESPARK-011 trial support the FDA approval of belzutifan plus lenvatinib for adults with advanced clear cell renal cell carcinoma.

In the phase 1b portion of the MELT-MM trial, elranatamab plus mezigdomide produced a 100% overall response rate in relapsed/refractory multiple myeloma.

Xiuning Le, MD, PhD, discusses the confirmatory SOHO-02 trial needed to convert sevabertinib’s accelerated approval to full approval.

A pooled analysis of the AMY2009 and AMY3001 trials showed daratumumab plus VCd yielded hematologic complete responses in cardiac-involved AL amyloidosis.

Health Canada approved epcoritamab plus lenalidomide and rituximab for relapsed/refractory grade 1 to 3a follicular lymphoma, backed by the EPCORE FL-1 trial.

David R. Gandara, MD, discusses how EMPOWER-Lung 1’s findings in KRAS G12C-mutated disease should inform the design of combination trials.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA MCGP Panel Votes in Favor of the Galleri Multicancer Early Detection Test
2
Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC
3
FDA Grants Approval to Lirafugratinib for Advanced Cholangiocarcinoma with FGFR2 Alteration
4
Approaching Cardiovascular Risk in Prostate Cancer Hormonal Therapy
5

